Crucial US Advisory Committee to Decide on Modifying Baby Hepatitis B Vaccine Recommendation
Following a postponement and a particularly heated meeting, a national immunization advisory committee was set to cast ballots on Friday regarding a potential change to the longstanding recommendation that all newborns be immunized against hepatitis B.
Intense Discussion and a Deferred Vote
The first day of the meeting on Thursday was characterized by fiery discussion over restricting access to the hepatitis B vaccine for babies and a choice to delay the ballot by a day to provide committee members extra time to examine the language. The group, which counsels the national health agency on vaccination protocols, had previously delayed on two occasions.
“Is there any concrete proof of damage of giving this vaccination before 30 days? Or is this conjecture?” inquired one panel member.
In answer, another attendee stated, “There is limited evidence about the enduring danger.”
Present Protocol and Likely Ramifications
The shot is presently advised for all infants within 24 hours of birth to prevent infection of hepatitis B, which can cause significant hepatic injury. It has been provided to 1.4 billion people for in excess of thirty years.
The meeting in Atlanta provided no recent proof of injuries resulting from the vaccine. Experts say any alteration to the present hepatitis B vaccination schedule could have major and extensive repercussions for infant and child health in the United States.
Group Membership and Recent Changes
The expert committee can only offer guidance to the director of the CDC. The group's roster has seen shifts in recent days, with the declaration that the committee’s most recent chair would step down for an agency job and be succeeded by a cardiac doctor who has been critical of other inoculations.
The panel includes a number of vaccination critics who are in agreement with a aim to revamp – and possibly, in some cases, scrap – longstanding vaccine advisories.
